Examining Ketamine Effects on Depression, Neuroplasticity, and Inflammation in Veterans With Parkinson's Disease
VA Office of Research and Development
Summary
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Description
This is a double-masked, active placebo-controlled, single dose randomized trial of intravenous (IV) ketamine versus remimazolam for depression in Veterans (N=80) with Parkinson's disease (PD). The investigators hypothesize that ketamine will have a strong safety and tolerability profile and improve depressive symptoms within 24 hours (Aim 1). Further, its antidepressant effects will be associated with modulation of both impaired neuroplasticity (Aim 2) and elevated inflammatory activity (Aim 3). To test these hypotheses, the investigators will use clinical assessments (of adverse events, tole…
Eligibility
- Age range
- 40–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Able to understand and provide written informed consent. 2. Is a United States Veteran. 3. Between 40-80 years old at the time of informed consent 4. Have neurologist-diagnosed idiopathic Parkinson's disease (PD) for at least six months prior to enrollment 5. History of inadequate response to at least one trial of antidepressant medication 6. On a stable regimen of all medications for at least 2 months prior to enrollment and have no planned medication changes during the period of active participation. 7. Commit to attend all in-person and remote study visits and partic…
Interventions
- DrugKetamine
intravenous ketamine infusion 0.5 mg/kg
- DrugRemimazolam
intravenous remimazolam infusion 0.03 mg/kg
Location
- San Francisco VA Medical Center, San Francisco, CASan Francisco, California